Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7108474 | 0.79 | CNR1 (0.53) | CNR1NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL17298905 | 0.79 | LOXL2 (0.46) | GABRA1KDM4E | |
| SCHEMBL19145297 | 0.73 | CNR1 (0.51) | CNR1NPC1RAB9AMMP13KDM4E | |
| SCHEMBL18644698 | 0.71 | HCAR2 (0.41) | GABRA1KDM4EALDH1A1 | |
| SCHEMBL20068742 | 0.71 | CNR1 (0.50) | CNR1NPC1RAB9AMMP13KDM4E | |
| SCHEMBL7103718 | 0.70 | CNR1 (0.52) | CNR1NPC1RAB9AKDM4EMAOB | |
| SCHEMBL18130913 | 0.70 | SIRT6 (0.52) | CNR1NPC1RAB9AMAOB | |
| SCHEMBL12500803 | 0.70 | SIRT6 (0.46) | GABRA1 | |
| SCHEMBL9331771 | 0.69 | HDAC1 (0.50) | CNR1NPC1RAB9AMMP13KDM4E | |
| SCHEMBL15033682 | 0.69 | METAP2 (0.46) | CNR1NPC1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | CNR1 927/4885NPC1 52/4885RAB9A 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.